Drug Development/R&D
New medicines lead to improved patient outcomes and societal benefits, but R&D is a long and costly process. Ongoing health economics research aims to find the right balance between incentivising manufacturers to innovate and ensuring affordable access for health systems.
The Trump Administration’s US Drug Pricing Proposal – What will happen next?
12 June 2025
This is the second in our series of Insights considering the implications of President Trump’s Executive Order on ‘Most Favoured Nation’ drug pricing. We know that…
Pharmacogenomics Testing: A Crucial Piece to Unlocking the Full Value of Medicines
5 June 2025
Join us for an online CERSI-PGx Health Economics Workshop on 10 June 2025, from 13:00–17:00 BST, with experts from NHS England, NICE, the University of Manchester, and Bangor University.
GLP-1 Receptor Agonists: Shifting Obesity Management
12 May 2025
The glucagon-like peptide-1 (GLP-1) receptor agonist market is experiencing rapid growth, with more than 150 drug candidates currently in development as reported by Research & Markets,…
The Importance of Diversity of Supply in Rare Diseases Markets
23 January 2025
Rare disease medicine markets often rely on single suppliers, increasing the risk of shortages and limiting treatment options. Our report explores how supplier diversity can enhance healthcare resilience and drive innovation, with actionable recommendations for policymakers.
What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?
19 November 2024
A critique of the recent EEPRU paper
The Cost of Drug Shortages
16 September 2024
Across the globe, drug shortages are becoming increasingly common.
Drug shortages are on the rise – but what is their impact?
16 September 2024
In this article, we discuss the global issue of drug shortages. We summarise our research where we developed a framework for quantifying the cost of a shortage, and through three case studies provide illustrative estimates of these costs.
Drug Shortages: What are the causes, consequences and pathways to a solution?
5 September 2024
Across the globe, drug shortages are becoming increasingly common across a range of therapeutic areas. Earlier this year, OHE published a report looking at the Dynamics…
Plan For A New EU Pharmaceutical Legislation: What Will It Mean For Pharmaceutical Innovation?
12 April 2024
The European Commission and European Parliament have set out their proposals for a reformed EU pharmaceutical legislation which could substantially change the incentive ecosystem for the first time in 20 years.